PreMD Inc. Reports Third Quarter Results and Appoints New Chief Financial Officer
...nsultant within the biotechnology industry. Previously, Ms. Auld was Chief Financial Officer of NeuroMedix Inc. and Interim Chief Financial Officer of arius Research Inc., and prior thereto, Chief Financial Officer of Transition Therapeutics Inc. Mr. Ron Hosking, who has been with PreMD over 11 years is ...Targets on the horizon: Emerging therapies and novel targets
...an cancer models: Abstract A 70. Scientists at arius Research, Inc., a biotechnology company based in T...dy was discovered through a technique developed at arius called FunctionFIRST™, a methodology that sc...olon, breast and prostate report researchers from arius Research, Inc., a biotechnology company based in T...ARIUS to Present at American Association for Cancer Research Annual Meeting
...tions Reveal New Findings - TORONTO, April 4 - arius Research Inc. (TSX: ARI), a biotechnology company ... CD44 can be linked to poorer chances of survival. arius anti-CD44 antibodies have previously been found to...f= "http://www.aacr.org/">www.aacr.org . About arius ARIUS is a biotechnology company discovering an...Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
- Laureate to Manufacture ARIUS' Product Candidate Trop-2 Signal Transduction Antibody - PRINCETON, N.J., Jan. 31 /PRNewswire/ -- Laureate Pharma, Inc., a full- service biopharmaceutical development and protein production company, today announced that it has entered ...Roche completes acquisition of ARIUS
- Gains access to new screening platform for antibody therapeutics BASEL, Switzerland, Sept. 24 /PRNewswire-FirstCall/ - Roche (SWX: ROG) announced today that it has completed the acquisition of 100% of the issued and outstanding shares and warrants of ARIUS Research (TSX: ARI). On September...ARIUS sale approved by shareholders
... TORONTO, Sept. 18 /PRNewswire-FirstCall/ - arius Research Inc., (TSX: ARI), a biotechnology company...ave of antibody therapeutics, today announced that arius Research Inc. shareholders and warrant holders app...ion of certain closing conditions. About ARIUS arius is a biotechnology company discovering and develop...ARIUS announces second quarter fiscal 2008 financial results
... TORONTO, July 11 /PRNewswire-FirstCall/ - arius Research Inc., (TSX: ARI), a biotechnology company... submission in the first quarter of 2008. - arius plans to have clinical trials' materials prepared ...Preparing for a pre-IND meeting with the FDA. - arius intends to have clinical trials' materials prepare...ARIUS presents new findings for anti-cancer antibody programs at AACR
...dies- TORONTO, April 15 /PRNewswire-FirstCall/ - arius Research Inc., (TSX: ARI), a biotechnology company...herapeutics 32, Tuesday, April 15, 2008, 8:00 AM arius has demonstrated that treatment with ARIUS' CD9 ta...herapeutics 32, Tuesday, April 15, 2008, 8:00 AM arius shows its Trop-2 targeting antibody, AR47A6.4.2, i...ARIUS announces first quarter fiscal 2008 financial results
... TORONTO, April 11 /PRNewswire-FirstCall/ - arius Research Inc., (TSX: ARI), a biotechnology company...r stem cell field. Maintaining this momentum, five arius abstracts have been selected for presentation in t... terms of the research collaboration agreement, arius has successfully met its obligations to da...ARIUS 2008 Annual and Special Meeting of Shareholders
... TORONTO, April 9 /PRNewswire-FirstCall/ - arius Research Inc. (TSX: ARI), a biotechnology company ...hursday, April 10th, 2008 at 10:00 a.m. Webcast: arius Research Inc.'s Annual and Special Meeting will be... will be archived for 12 months. About arius ...ARIUS recognized for entrepreneurial excellence
...eneurs TORONTO, April 7 /PRNewswire-FirstCall/ - arius Research Inc. (TSX: ARI), a biotechnology company ...ed great value to the marketplace. About ARIUS arius is a biotechnology company discovering and develop...ave of antibody therapeutics. Established in 1999, arius has built a proprietary technology platform, Funct...